From metallodrugs to metallodendrimers for nanotherapy in oncology: A concise overview

Current Medicinal Chemistry

Volumn 19, Issue 29, 2012, Pages 4995-5010

  El Kazzouli, S ^a   El Brahmi, N ^a,d   Mignani, S ^a   Bousmina, M ^b   Zablocka, M ^c   Majoral, J P ^a,d  

^a MOHAMMED V UNIVERSITY   (Morocco)

^b HASSAN II ACADEMY OF SCIENCE AND TECHNOLOGY   (Morocco)

^c CENTRE OF MOLECULAR AND MACROMOLECULAR STUDIES   (Poland)

^d LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

Author keywords

Dendrimers; Drugs; Metal complexes; Nanotheraphy; Oncology

Indexed keywords

CARBOPLATIN; CISPLATIN; DENDRIMER; EPTAPLATIN; GOLD COMPLEX; LOBAPLATIN; METAL COMPLEX; METALLODENDRIMER; METALLODRUG; NEDAPLATIN; ORGANOMETALLIC COMPOUND; OXALIPLATIN; PLATINUM COMPLEX; SILVER COMPLEX; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIODEGRADATION; BLADDER CANCER; CANCER CHEMOTHERAPY; CONJUGATE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TARGETING; ENCAPSULATION; HEAD CANCER; HEMOLYSIS; HUMAN; LUNG CANCER; MACROMOLECULE; MICELLE; NECK CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; REVIEW;

ANIMALS; COORDINATION COMPLEXES; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; METALS; NANOMEDICINE; NEOPLASMS;

EID: 84870420716     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311209024995     Document Type: Review

References (193)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. A Cancer Journal for Clinicians, 2011, 61, 69-90.
2. Kummar, S.; Chen, H.X.; Wright, J.; Holbeck, S.; Millin, M.D.; Tomaszewski, J.; Zweibel, J.; Collinsa, J.; Doroshow, J. H. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat. Rev. Drug Discovery, 2010, 9, 843-856.
3. Utreja, P.; Jain, S.; Tiwary, A.K. Localized delivery of paclitaxel using elastic liposomes: Formulation development and evaluation. Drug Delivery, 2011, 18, 367-376.
4. Szebeni, J.; Muggia, F.M.; Alving, C.R. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. J. Natl Cancer Inst., 1998, 90,300-306.
5. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 2001, 37, 1590-1598.
6. Available at: http://www.abraxisbio.com/products-abraxaneUS.htm [Accessed on May 2011]
7. Dreis, S.; Rothweiler, F.; Michaelis, M.; Kreuter, J.; Langer, K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm., 2007, 341, 207-2014.
8. Cosco, D.; Paolino, D.; Muzzalupo, R.; Celia, C.; Caponio, D.; Picci N. P.; Fresta, M. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomedical Microdevices, 2009, 11, 1115-1125.
9. Vodovozova, E.L.; Kuznetsova, N.R.; Gaenko, G.P.; Molotkovsky, J.G. Liposomal formulation of a methotrexate diglyceride conjugate: Activity toward a culture of methotrexate-resistant leukemia cells. Russ. J. Bioorg. Chem., 2007, 33, 436-438.
10. Ogier, J.; Arnauld, T.; Doris; E. Recent advances in the field of nanometric drug carriers. Future Med. Chem. 2009, 1, 693-711.
11. Zhang, L. H.; Gu,F. X.; Chan, J. M.; Wang, A.Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83,761-769.
12. Irvine, D. J. Drug delivery: One nanoparticle, one kill. Nature Materials, 2011, 10, 342-343.
13. Amijji, M. M. Nanotechnology - Improving Targeted Delivery. Nanotechnology, 2007, 53-56.
14. Astruc, D.; Boisselier, E.; Ornelas, C. E. Dendrimers desiged for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedecine. Chem. Rev., 2011, 110, 1857-1959.
15. Tomalia, D.A.; Reyna, L.A.; Swenson, S.; Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans., 2007, 35, 61-67.
16. Petros, R.A.; DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature Reviews Drug Discovery, 2010, 9, 615-627.
17. Jorgensen, L.; Nielsen, H.M. Delivery Technologies for Biopharmaceuticals, Eds. Wiley, 2009.
18. Kumar, C. Nanomaterials for Cancer Therapy, Eds. Wiley-VCH, 2006.
19. Agarwal, A.; Asthana, A.; Gupta, U.; Jain, N.K. Tumour and dendrimers: a review on drug delivery aspects. J. Pharm. Pharmacol., 2008, 60, 671-688.
20. Parveen, S.; Misra, R.; Sahoo, S.K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomed. Nanotechnol. Biol. Med., 2012, 8, 147-166.
21. Utreja, P.; Jain, S.; Tiwary, A.K. Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects. Current Drug Delivery, 2010, 7, 152-161.
22. Brunton, L. L.; Lazo, J. S.; Parker, K. L. T. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition, Eds. McGraw-Hill (N-Y), 2006.
23. Kayser,O.; Lemke, A.; Hernandez-Trejo, N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol., 2005, 6, 3-5.
24. Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: a new class of nanoscopic containers and drug delivery devices. Eur. Polymer. J., 2003, 1741-1771.
25. Boas, U.; Heegaard, P. M. Dendrimers in drug research. Chem. Soc. Rev., 2004, 33, 43-53.
26. Patri, A. K.;, Majoros, I. J.; Baker, J. R. Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol,. 2002, 6, 466-47.
27. Kievit, F.M.; Zhang, M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc. Chem. Res., 2011, 44, 853-863.
28. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nature Reviews Cancer, 2005, 5, 161-171.
29. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nature Reviews Cancer, 2006, 6, 688-701
30. Misra,R.; Acharya, S.; Sahoo, S.K. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discovery Today, 2010, 15, 842-850.
31. Wong, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs, Nature Reviews Drug Discovery, 2005, 4, 307-320.
32. Gabano, E.; Ravena, M.; Osella, D. The drug targeting and delivery approach applied to Pt-antitumour complexes. A coordination point of view. Curr. Med. Chem., 2009, 16, 4544-4580.
33. Gabano, E.; Ravera, M.; Colangelo, D., Osella, D. Bioinorganic chemistry : the study of the fate of platinum-based antitumor drugs. Current Chem. Biology, 2007, 1, 278-289.
34. Wu, B.; Droge, P.; Davey, C.A. Site selectivity of platinum anticancer therapeutics. Nat. Chem. Biol., 2008, 4, 110-112.
35. Wong, E.; C. M. Giandomenico, C.M. Current status of Platinum-based antitumor drugs. Chem. Rev., 1999, 99, 245-2466.
36. Jansen, B. A.; Zwan, J.; Reedijk, J.; Dulk, H.; Brouwer, J. A tetranuclear platinum compound designed to overcome cisplatin resistance. Eur. J. Inorg. Chem. 1999, 9, 1429-1433.
37. Kasparkova, J.; Novakova, O.; Marini, V.; Najajreh, Y.; Gibson, D.; Perez, J. M.; Brabec, V.J. Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand-Mechanistic studies on antitumor action. Biol. Chem., 2003, 78, 47516-47525.
38. Pil, P. and S. J. Lippard, S.J. Encyclopedia of Cancer, Bertino, J.R. Eds. Academic Press: San Diego, CA, 1997.
39. Chu, G. J. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. Biol. Chem., 1994, 269, 787-790.
40. Hambley, T. W. The influence of structure on the activity and toxicity of Pt anti-cancer drugs, Coord. Chem. Rev., 1997, 66, 181-223.
41. Lee, Y.A.; Chung, Y. K.; Sohn, Y. S., Linkage Isomerism Dependent on Solvent and Temperature. Synthesis and Structural Properties of Diamineplatinum( II) Complexes of Allyl-and Diallylmalonate Ligands. Inorg. Chem,. 1999, 38, 531-537.
42. 4+)) influenced by copper homeostasis. Biochem. Pharmacol., 2007,73, 1270-1279.
43. Zhang, J. C.; Liu, L.; Gong, Y. Q.; Zheng,X.M.; Yang, M.S.; Cui, J.R.; Shen, S.G. Synthesis, characterization and antiyumor activity of new type of binuclear platinum(II) complexes. Eur. J. Med. Chem., 2009, 44, 2322-2327.
44. Wang, X. Fresh platinum complexes with promising antitumor activity. Anticancer Agents in Medicinal Chemistry, 2010, 10, 396-411.
45. Gao, C.; Xu, G.; Gou, S. Antitumor dinuclear platinum(II) complexes derived from a novel chiral ligand. Bioorganic & Med. Chem. Letters, 2011, 21, 6386-6388.
46. Johnson, A.; Qu, Y.; Houten, B. V.; Farrell, N. B ↑ZDNA conformationalchanges induced by a dinuclear bis(platinum) complexes. Nucl. Acids Res., 1992, 20, 1697-1703.
47. Fergusson, M.J.; Ahmed, F.Y.; Cassidy, J. The role of pro-drug therapy in the treatment of cancer. J. Drug Resist. Updates, 2001, 4, 225-232.
48. Dhar S., Kolishetti N., Lippard S.J., Farokhzad O.C., Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A, 2011, 108, 1850-1862.
49. Kratz, F.; Schütte, M.T. Anticancer metal complexes and tumour targeting strategies. Cancer J., 1998, 11, 60-67.
50. Momekov, G.; Momekova, D. Recent developments in antitumour platinum coordination compounds. Expert Opin. Ther. Patents, 2006, 16, 1383-1403.
51. Molema, G. In Drug Targeting Organ-Specific Strategies, Molema, G.; Meijer, D.K.F., Eds. Wiley-VCH: Weinheim, 2001, pp. 1-20.
52. Dancey J.E.; Chen, H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 2006, 5, 649-659.
53. Descôteaux, C.; Leblanc, V.; Bélanger, G.; Parent, S.; Asselin, E.; Bérubé, G. Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta. Steroids, 2008, 73, 1077-1089.
54. Karl, J., Gust, R.; Spruss, T.; Schneider, M.R.; Schönenberger, H.; Engel, J.; Wrobel, K.-H.; Lux, F., Haeberlin, S.T. Ring-Substituted[1,2-Bis(4- hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: Compounds with a Selective Effect on the Hormone-Dependent Mammary Carcinoma. J. Med. Chem., 1988, 31, 72-83.
55. Gust, R.; Faderl, M.; Schönenberger, H. [Aqua-1-(2,6-dichloro-4- hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties. J. Cancer Res. Clin. Oncol., 2000, 126, 647-654.
56. Vessières, A.; Top, S.; Beck, W.; Hillard, E.; Jaouen, G. Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. Dalton Trans., 2006, 2006, 529-541.
57. Top, S.; Kaloun, E.B.; Vessières, A.; Leclercq, G.; Laïos, I.; Ourevitch, M.; Deuschel, C.; McGlinchey, M.J.; Jaouen, G. Tamoxifen derivatives for delivery of the anti-tumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour. ChemBioChem, 2003, 4, 754-761.
58. Criado, J.J.; Hemera, M.C.; Palomero, M.F.; Medarde, M.; Rodriguez, E.; Marin J.J.G. Synthesis and characterization of a new bile acid and platinum( II) complex with cytostatic activity. J. Lipid Res., 1997, 38, 1022-1032.
59. Paschke, R.; Kalbitz, J.; Paetz, C. Novel spacer linked bile-acidcisplatin compounds as a model for specific drug delivery, synthesis and characterization. Inorg. Chim. Acta, 2000, 304, 241-249.
60. Vitols, K.S.; Montejano, Y.; Duffy, T.; Pope, L.; Grundler, G.; Huennekens, F.M. Platinum-folate compounds: synthesis, properties and biological activity. Adv. Enzyme Regul., 1987, 26, 17-27.
61. Aronov, O.; Horowitz, A.T.; Gabizon, A.; Gibson, D. Folatetargeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjugate Chem., 2003, 14, 563-574.
62. Gabano, E.; Ravera, M.; Colangelo, D.; Osella, D. Bioinorganic chemistry: the study of the fate of platinum-based antitumour drugs. Curr. Chem. Biol., 2007, 1, 278-289.
63. Pil, P.M.; Lippard, S.J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science, 1992, 256, 234-237.
64. Dominguez, M.F.; Macias, R.I.R.; Izco-Basurko, I.; de La Fuente, A.; Pascual, M.J.; Criado, J.M.; Monte, M.J.; Yajeya, J.; Marin, J.J.G. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J. Pharmacol. Exp. Ther., 2001, 297, 1106-1112.
65. Natile, G.; Coluccia, M. In Metal Ions in Biological Systems, Sigel, A.; Sigel, H., Eds.; Marcel Dekker: New York, Vol. 42 (Metal Complexes in Tumor Diagnosis and as Anticancer Agents), 2004, pp. 209-250.
66. 2O {Boh=6-(benzylamino)-2-[(3- (hydroxypropyl)-amino]-9-isopropylpurine ,Bohemine}. J. Inorg. Biochem., 2003, 94, 307-316.
67. Messere, A.; Fabbri, E.; Borgatti, M.; Gambari, R.; Di Blasio, B.; Pedone, C.; Romanelli, A. Antiproliferative activity of Pt(II) and Pd(II) phosphine complexes with thymine and thymidine. J. Inorg. Biochem., 2007, 101, 254-260.
68. Ohya, Y.; Oue, H.; Nagatomi, K.; Ouchi T. Design of macromolecular prodrug of cisplatin using dextran with branched galactose units as targeting moieties to hepatoma cells. Biomacromolecules, 2001, 2, 927-933.
69. Dalla Via, L.; Gia, O.; Marciani Magno, S.; Dolmella, A.; Marton, D.; Di Noto, V. Synthesis, characterization and biological activity of platinum(II) complexes with L-and D-ornithine ligands. Inorg. Chim. Acta, 2006, 359, 4197-4206.
70. Moradell, S.; Lorenzo, J.; Rovira, A.; van Zutphen, S.; Avilés, F.X.; Moreno, V.; de Llorens, R.; Martinez, M.A.; Reedijk, J., Llobet, A. Water-soluble platinum(II) complexes of diamine chelating ligands bearing amino-acid type substituents: the effect of the linked amino acid and the diamine chelate ring size on antitumor activity, and interactions with 50-GMP and DNA. J. Inorg. Biochem., 2004, 98, 1933-1946.
71. Mukhopadhyay, S.; Barnés, C.M.; Haskel, A.; Short, S.M.; Barnes, K.R.; Lippard, S.J. Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature. Bioconjug. Chem., 2008, 19, 39-49.
72. Bloemink, M.J.; Dorenbos, J.P.; Heetebrij, R.J.; Keppler, B.K.; Reedijk, J.; Zahn, H. New Antitumor platinum compounds linked to amino phosphonic acids which lose the phosphonate and tertiary amine ligand upon binding to nucleic acids. Inorg. Chem. 1994, 33, 1127-1132.
73. Galanski, M.; Slaby, S.; Jakupec, M.A.; Keppler, B.K. Synthesis, Characterization, and in vitro Antitumor Activity of Osteotropic Diam(m)ineplatinum(II) Complexes Bearing a N,N-Bis(phosphonomethyl) glycine ligand. J. Med. Chem., 2003, 46, 4946-4951.
74. Harper, B.W. ; Krause-Heuer, A.M.; Grant, M.P.; Manohar, M.; Garbutcheon-Singh, K. B.; Aldrich-Wright, J. R. Advances in Platinum Chemotherapeutics, Chem. Eur. J., 2010, 16, 7064-7077.
75. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov., 2003, 2, 347-360.
76. Duncan, R.; Dimitrijevic, S.; Evagorou, E.G. The role of polymer conjugates in the diagnosis and treatment of cancer. S. T. P. Pharma Sci., 1996, 6, 237-263.
77. Machado, M. de L.; Neuse, E.W.; Perlwitz, A.G. Water-soluble polyamides as potential drug carriers, 5. Carboxy-functionalized polyaspartamides and copolyaspartamides. Angew. Makromol. Chem., 1992, 195, 35-56.
78. Neuse, E.W.; Patel, B.B.; Mbonyana, C.W.N. cisdiaminedichloroplatinum( II) complexes reversibly bound to water-soluble polyaspartamide carriers for chemotherapeutic applications. Platinum coordination to preformed, carrier-attached ethylenediamine ligands. J. Inorg. Organomet. Polym., 1991, 1, 147-165.
79. Schechter, B.; Caldwell, G.; Meirim, M.G.; Neuse, E.W. Preliminary toxicological studies of selected water-soluble polymerplatinum conjugates. Appl. Organomet. Chem., 2000, 14, 701-708.
80. Hartinger. C,G,; Nazarov, A.A.; Ashraf, S.M.; Dyson, P.J.; Keppler, B.K. Carbohydrate-metal complexes and their potential as anticancer agents. Curr. Med. Chem., 2008, 15, 2574-259.
81. Gianasi, E.; Buckley, R.G.; Latigo, J.; Wasil, M.; Duncan R. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Target., 2002, 10, 549-556.
82. Lin, X.; Zhang, Q.; Rice, J.R.; Stewart, D.R.; Nowotnik, D.P.; Howell, S.B. Improved targeting of platinum chemotherapeutics: the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur. J. Cancer, 2004, 40, 291-297.
83. Nishiyama, N.; Okazaki, S.; Cabral, H.; Miyamoto, M.; Kato, Y.; Sugiyama, Y.; Nishio, K.; Matsumura, Y.; Kataoka, K. Novel Cisplatin-Incorporated Polymeric Micelles Can Eradicate Solid Tumors in Mice, Cancer Research, 2003, 63, 8977-8983.
84. Cabral, H.; Nishiyama, N.; Okazaki, S.; Koyama, H.; Katoaka, K. Preparation and biological properties of dichloro(1,2-diaminocyclohexane) platinum(II) (DACHPt)-loaded polymeric micelles. J. of Control. Release, 2005, 101, 223-232.
85. Murakami, M.; Cabral, H.; Matsumoto, Y.; Wu, S.; Kano, M.R.; Yamori, T.; Nishiyama, N.; Kataoka, K. Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting. Sc. Transl. Med., 2011, 3, 64, 64ra2.
86. Gál, M.; Híves, J.; Laus, M.; Sparnacci, K.; Ravera, M.; Gabano, E.; Osella, D. Electrostatic Interaction of Negatively Charged Core-Shell Nanoparticles with Antitumoral Cationic Platinum-Based Complexes. Eur. J. Inorg. Chem., 2011, 22, 3289-3294.
87. Babincová, M.; Altanerová, V.; Altaner, C.; Bergemann, C.; Babinec, P. In Vitro Analysis of Cisplatin Functionalized Magnetic Nanoparticles in Combined Cancer Chemotherapy and Electromagnetic Hyperthermia. IEEE Trans. Nanobiosci., 2008, 7, 15-19.
88. Chavain, N.; Biot, C. Organometallic complexes: new tools for chemotherapy. Curr. Med. Chem., 2010, 17, 2729-274.
89. Guo, M.; Guo, Z.; Sadler, P.J. Titanium(IV) targets phosphoesters on nucleotides: implications for the mechanism of action of the anticancer drug titanocene dichloride. J. Biol. Inorg. Chem., 2001, 6, 698-707.
90. Kelter, G.; Sweeney, N. J.; Strohfeldt, K.; Fiebig, H. H.; Tacke, M. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. Anti-Cancer Drugs, 2005, 16, 1091-1098.
91. Riccardi, A.; Ferlini, C.; Meco, D.; Mastrangelo, R.; Scambia, G.; Riccardi, R. Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur. J. Cancer, 1999, 35, 86-90.
92. O'Connor K, G. C.; Tacke, M.; Rehmann, F. J.; Strohfeldt, K.; Sweeney, N.; Fitzpatrick, J. M.; Watson, R. W. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptoticpathway in prostate cancer cells. Apoptosis, 2006, 11, 1205-1214.
93. Pampillón, C.; Claffey, J.; Hogan, M.; Tacke, M. Novel achiral titanocene anti-cancer drugs synthesised from bis-N,Ndimethylamino fulvene and lithiated heterocyclic compounds. Biometals, 2008, 21, 197-204.
94. Claffey, J.; Hogan, M.; Müller-Bunz, H.; Pampillón, C.; Tacke, M.Oxali-Titanocene Y: A potent anticancer drug. ChemMedChem, 2008, 3, 729-731.
95. Fiorina, V. J.; Dubois, R. J.; Brynes, S. Ferrocenyl polyamines as agents for the chemoimmunotherapy of cancer. J. Med. Chem., 1978, 21, 393-395.
96. Jaouen, G.; Top, S.; Raynaud, J.P. French Patent 2725720-AI, 1994.
97. Top, S.; Tang, J.; Vessières, A.; Carrez, D.; Provot, C.; Jaouen, G. Ferrocenyl hydroxytamoxifen: a prototype for a new range of oestradiol receptor site-directed cytotoxics. Chem. Commun., 1996, 8, 955-956.
98. Biot, C.; Glorian, G.; Maciejewski, L. A.; Brocard, J. S. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocenechloroquine analogue. J. Med. Chem., 1997, 40, 3715-3718.
99. Chohan, Z. H.; Scozzafava, A.; Supuran, C. T. Unsymmetrical 1,1'-disubstituted Ferrocenes: Synthesis of Co(II), Cu(II), Ni(II) and Zn(II) Chelates of Ferrocenyl-1-thiadiazolo-1-tetrazole, -1-thiadiazolo-1-triazole and -1-tetrazolo-1□ -triazole with Antimicrobial Properties. J. Enzyme Inhib. Med. Chem., 2002, 17, 261-266.
100. Hartinger. C.G., Zorbas-Seifried, S.; Jakupec, M.A.; Kynast, B.; Zorbas, H.; Keppler, B.K. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1Hindazole) ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100, 891-904.
101. Bratsosa, I.; Jednera, S.; Gianferrarab, T.; Alessio, E. Ruthenium Anticancer Compounds:Challenges and Expectations, Chimia, 2007, 61, 692-697.
102. Hartinger, C.G.; Jakupec, M.A.; Zorbas-Seifried,S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. KP1019, a new redoxactive anticancer agent -preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodiversity 2008, 5, 2140-2155.
103. Tan, C.; Lai, S.; Wu, S., Hu, S.; Zhou, L.; Chen, Y.; Wang, M.; Zhu, Y.; Lian, W.; Peng, W.; Ji, L.; Xu, A. Nuclear Permeable Ruthenium(II) β-Carboline Complexes Induce Autophagy To Antagonize Mitochondrial Mediated Apoptosis. J. Med. Chem., 2010, 53, 7613-7624.
104. Ang, W. H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L., Dyson, P. J. Development of organometallic ruthenium -arene anticancer drugs that resist hydrolysis. Inorg. Chem., 2006, 45, 9006-9013.
105. Vock, C. A. Renfrew, A.K. ; Scopelliti, R.; Juillerat-Jeanneret, L. ; Dyson. P. J. Influence of the diketonato ligand on the cytotoxicities of [Ru( 6-pcymene)( R2acac)(PTA)]+complexes (PTA = 1,3,5-triaza-7-phosphaadamantane). Eur. J. Inorg. Chem., 2008, 10, 1661-1671.
106. Nowak-Sliwinska, P.; van Beijnum, J.R.; Casini, A.; Nazarov, A.A.; Wagnières, G.; van den Bergh, H.; Dyson, P.J.; Griffioen, A.W. Organometallic Ruthenium(II) arene compounds with antiangiogenic activity. J. Med. Chem., 2011, 54, 3895-3902.
107. Melchart, M.; Sadler, P. J. Bioorganometallics, Ed. G. Jaouen, Wiley-VCH, Weinheim, 2006.
108. Berger, I.; Hanif, M.; Nazarov, A.A.; Hartinger, C.G.; John, R.O.; Kuznetsov, M.L.; Groessl, Michael.; Schmitt, F.; Zava, O.; Biba, F.; Arion, V. B.; Galanski, M.; Jakupec, M. A.; Juillerat-Jeanneret, L.; Dyson, P.J.; Keppler, B.K. In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. Chem. Eur. J., 2008, 14, 9046-9057.
109. Hartinger, C. G.; Nazarov, A. A.; Ashraf, S. M.; Dyson, P. J.; Keppler, B. K. Carbohydrate-metal complexes and their potential as anticancer agents. Curr. Med. Chem., 2008, 15, 2574-2591.
110. Ange W. H.; De Luca, A.; Chapuis-Bernasconi, C.; Juillerat-Jeanneret, L.; Lo Bello, M.; Dyson, P. J. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. ChemMedChem, 2007, 2, 1799-1806.
111. Patitungkho, S.; Adsule, S.; Dandawate, P.; Padhye, S.; Ahmad, A.; Sarkar, F. H. Synthesis, characterization and anti-tumor activity of moxifloxacincopper complexes against breast cancer cell lines, Bioorg. Med. Chem. Letters, 2011, 21, 1802-1806.
112. Bregman, H.; Williams, D. S.; Atilla, G. E.; Carroll, P. J.; Meggers, E. An organometallic inhibitor for glycogen synthase kinase 3. J. Am. Chem. Soc., 2004, 126, 13594-13595.
113. Williams, D. S.; Atilla, G. E.; Bregman, H.; Arzoumanian, A.; Klein, P. S.; Meggers, E. Switching on a signaling pathway with an organoruthenium complex. Angew. Chem .Int. Ed., 2005, 117, 2020-2023.
114. Williams, D. S.; Atilla, G. E.; Bregman, H.; Arzoumanian, A.; Klein, P. S.; Meggers, E. Switching on a signaling pathway with an organoruthenium complex. Angew. Chem. Int. Ed., 2005, 44, 1984-1987.
115. Debreczeni, J. E.; Bullock, A. N.; Atilla, G. E.; Williams, D. S.; Bregman, H.; Knapp, S.; Meggers, E. Ruthenium Half-Sandwich complexes bound to protein kinase Pim-1. Angew. Chem., Int. Ed., 2006, 45, 1580-1585.
116. Kunick, C.; Ott, I. Metal complexes as protein kinase inhibitors, Angew. Chem. Int. Ed., 2010, 49, 5226-5227.
117. Schmid, W. F.; John, R. O.; Arion, V. B.; Jakupec, M. A.; Keppler, B. K. Highly antiproliferative ruthenium(II) and osmium(II) arene complexes with paullone-derived ligands. Organometallics, 2007, 26, 6643-6652.
118. Gaiddon, C.; Jeannequin, P.; Bischoff, P.; Pfeffer, M.; Sirlin, C.; Loeffler, J. P. Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. J. Pharmacol. Exp. Ther., 2005, 315, 1403-1411.
119. Mendoza-Ferri, M.-G.; Hartinger, C. G.; Eichinger, R. E.; Stolyarova, N.; Severin, K.; Jakupec, M. A.; Nazarov, A. A.; Keppler, B. K. Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds. Organometallics, 2008, 27, 2405-2407
120. Ruiz-Azuara, L. R.; Bravo-Gomez, M.E. Copper compounds in cancer therapy. Curr. Med. Chem, 2010, 17, 3606-3615.
121. Wong, E.; Giandomenico, C. M. Current Status Of Platinum-Based Antitumor Drugs. Chem. Rev., 1999, 99, 2451-2466.
122. Casini, A.; Hartinger, C.; Gabbiani, C.; Mini, E.; Dyson, P. J.; Keppler, B. K.; Messori, L. Gold(III) compounds as anticancer agents: Relevance of gold-protein interactions for their mechanism of action. J. Inorg. Biochem., 2008, 102, 564-575.
123. Carotti, S.; Guerri, A.; Mazzei, T.; Messori, L.; Mini, E.; Orioli, P. Gold(III) compounds as potential antitumor agents: Cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes. Inorg. Chim. Acta, 1998, 281, 90-94.
124. Marcon, G.; Carotti, S.; Coronnello, M.; Messori, L.; Mini, E.; Orioli, P.; Mazzei, T.; Cinellu, M. A.; Minghetti, G. Gold(III) complexes with bipyridyl ligands: Solution chemistry, cytotoxicity, and DNA binding properties. J. Med. Chem., 2002, 45, 1672-1677.
125. Abbate, F.; Orioli, P.; Bruni, B.; Marcon, G.; Messori, L. Crystal structure and solution chemistry of the cytotoxic complex 1,2- dichloro(ophenanthroline) gold(III) chloride. Inorg. Chim. Acta, 2000, 311, 1-5.
126. Berners-Price, S.J.; Johnson, R.K.; Giovenella, A. J.; Faucette, L. F.; Mirabelli, K.; Sadler, P. J. Antimicrobial and anticancer activity of tetrahedral, chelated, diphosphine silver(I) complexes : comparison with copper and gold. J. Inorg. Biochem., 1988, 33, 285-295.
127. Medvetz, D.A.; Hindi, K.M.; Panzner, M.J.; Ditto, A.J.; Yun, Y. H.; Youngs, W.J. Anticancer activity of Ag(I) N-Heterocyclic carbene complexes derived from 4,5-dichloro-1H-Imidazole. Metal-Based Drugs, 2008, 2008: 384010, doi:10.1155/2008/384010
128. Kascatan-Nebioglu, A.; Panzner, M. J.; Tessier, C. A.; Cannon, C. L.; Youngs, W. J. N-Heterocyclic carbene-silver complexes: A new class of antibiotics. Coord. Chem. Rev., 2007, 251, 884-895.
129. Samad, A.; Alam, M. D. I.; Saxena, K. Dendrimers: a class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr. Pharm. Des., 2009, 15, 2958-2969.
130. Svenson, S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm., 2009, 71, 445-462.
131. Oliveira, J. M.; Salgado, A. J.; Sousa, N.; Mano, J. F.; Reis, R. L. Dendrimers and Derivatives as a Potential Therapeutic Tool in Regenerative Medicine Strategies -A Review. Progress in Polymer Science, 2010, 35, 1163-1194.
132. Rolland, O.; Turrin, C.-O.; Caminade, A.-M.; Majoral, J.-P. Dendimers and nanomedicine: multivalency in action. New. J. Chem., 2009, 33, 1809-1824.
133. Z. Y.; Huang, W.; Liu, J.; Zhu, X.; Yan, D. self-assembly of hyperbranched polymers and its biomedical applications. Adv. Mater., 2010, 22, 4567-4590.
134. Yang, H.; Kao, W. dendrimers for pharmaceutical and biomedical applications. J. Biomater. Sci. Polymer Edn, 2006, 17, 3-19.
135. Mintzer, M. A.; Grinstaff, M. W. Biomedical aplications of dendrimers: a tutorial. Chem. Rev. Soc., 2010, 40, 173-190.
136. Svenson, S., Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm., 2009, 71, 445-462.
137. Cloninger, M. J. Biological applications of dendrimers. Curr. Opin. Chem. Biol., 2002, 6, 742-748.
138. Najlah, M.; D'Emanuele, A. Synthesis of dendrimers and drug-dendrimer conjugates for drug delivery. Curr. Opin. Drug Discovery Dev. 2007, 10, 756-767.
139. Jain, N. K.; Gupta, U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert Opinion, 2008, 4, 1035-1052.
140. Samad, A.; Alam, M.I.; Saxena, K. Dendrimers: a class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr. Pharm. Des., 2009, 15, 2958-2969.
141. Gohel, M. C.; Parikh, R.K. Dendrimer: an overview, Pharmainfo.net 2009.
142. El Kazzouli, S.; Mignani, S.; Bousmina, M.; Majoral, J-P., Dendrimer therapeutics: covalent and ionic attachments. New J. Chem., 2012, 36, 227-240.
143. Medina, S.H.; El-Sayed, E.H. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem. Rev., 2009, 109, 3141-3157.
144. Tekade, R.K.; Kumar, P.V.; Jain, N.K. Dendrimers in oncology: an expanding horizon. Chem. Rev., 2009, 109, 49-87.
145. Paleos, C.M.; Tsiourvas, D.; Sideratou, Z.; Tziveleka, L-A. Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opinion, 2010, 7, 1387-1398.
146. van Haandel, L.; Stobaugh, J. F. Bioanalytical method development for a generation 5 polyamidoamine folic acid methotrexate conjugated nanoparticle. Anal. Bioanal. Chem., 2010, 397, 1841-1852.
147. Fox, M.E.; Guillaudeu, S.; Fréchet, J. M. ; Jerger, K. ; Macaraeg, N. ; Szoka, F. C. Synthesis and in vivo antitumor efficacy of PEGylated poly(L-lysine) dendrimer-camptothecin conjugates. Mol. Pharm., 2009, 6, 1562-1572.
148. Guillaudeu, S.J.; Fox, M. E. ; Haidar, Y. M. ; Dy, E. E. ; Szoka, F. C. ; Fréchet, J. M. PEGylated dendrimers with core functionality for biological applications. Bioconjugate Chem., 2008, 19, 461-469.
149. Thomas, T.P.; Choi, S.K.; LI, M-H.; Baker, J. R. Design of riboflavinpresenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery. Bioorg. Med. Chem. Letters, 2010, 20, 5191-5194.
150. Jiang, Y-Y.; tang, G-T.; Zhang, L-H. ; Kong, S-Y. ; Zhu, S-J. ; Pei, Y-Y. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. Journal of Drug Targeting, 2010, 18, 389-403.
151. Hong, S.; Leroueil, P. R.; Majoros, I. J. ; Orr, B.G. ; Baker, J.R., Holl, M.M.B. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chemistry & Biology, 2007, 14, 107-1155.
152. Myung, J. H.; Gajjar, K. A.; Saric, J.; Eddington, D. T.; Hog, S. Dendrimermediated multivalent binding for the enhanced capture of tumor cells. Angew. Chem. Int. Ed., 2011, 50, 11769-11772.
153. Menjoge, A. R.; Kannan, R. M.; Tomalia, D. A. Dendrimer-based drug and imaging conjugates: desig considerations for nanomedical applications. Drug Discovery Today, 2010, 15, 171-185.
154. Jain, K.; Kesharwani, P.; Gupta, U.; Jain, N.K. Dendrimer toxicity: let's meet the challenge. Int. J. Pharm., 2010, 394, 122-142.
155. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Advanced Drug Delivery Reviews, 2005, 57, 2215-2237.
156. Mishra, V.; Gupta, U.; Jain, N.K. Surface-engineered dendrimers: a solution for toxicity issues. J. Biomater. Sci., Polym. Ed., 2009, 20, 141-166.
157. Available at: http://www.fiercedrugdelivery.com/story/eli-lilly- advancesdrug-delivery-tech-deals-starpharma-arecor/2011-12-20?utm-medium= nl&utm-source=internal [Accessed on January 2012].
158. Le Berre, V.; Trévisiol, E. ; Dagkessamanskaia, A. ; Sokol, S. ; Caminade, A-M. ; Majoral, J-P.; Meunier, B. ; François, J. Dendrimeric coating of glass slides for sensitive DNA microarrays analysis. Nucleic Acids Res., 2003, August 15; 31(16): e88.
159. Trevisiol, E. ; Le Berre, V. ; Leclaire, J. ; Pratviel, G. ; Caminade, A-M. ; Majoral, J-P. ; Francois, J. ; Meunier, B. Dendrislides, dendrichips: a simple chemical functionalization of glass slides with phosphorus dendrimers as an effective means for the preparation of biochips. New. J. Chem., 2003, 27, 1713-1719.
160. Available at: http://www.dendris.fr/wp-content/uploads/2011/09/ Dendristechnology-dendrimers.pdf [Accessed on january 2012]
161. McNerny, D. Q.; Leroueil, P. R.; Baker, J. R. Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals. Nanomed Nanobiotechnol., 2010, 2, 249-259.
162. Zuckerman, S.T.; Kao, W.J. Nanomaterials and Biocompatibility: BioMEMS and Dendrimers. Nanotechnology in Drug Delivery, 2009, 7, 193-228.
163. Kitchens, K. M.; Ghandehari, H. PAMAM Dendrimers as nanoscale oral drug delivery systems. Nanotechnology in Drug Delivery, 2009, 7, 423-459.
164. Gilies, E.R., Fréchet, M. J. Dendrimers and dendritic polymers in drug delivery. Drug Discovery Today, 2005, 10, 35-43.
165. Venuganti, V. V.; Sahdev, P.; Hildreth, M. ; Guan, X.; Perumal, O. Structure-skin permeability relationship of dendrimers. Pharm. Res., 2011, DOI 10.1007/s11095-011-455-0.
166. Venuganti, V.V.K.; Perumal, O. Poly(amidoamine) dendrimers as skin penetration enhancers : influence of charge, generation, and concentration. J. Pharm. Sci., 2009, 98, 2345-2356.
167. Dong, Z.; Katsumi, H.; Sakane, T.; Yamamoto, A. Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly aborbable drugs in rats. Int. J. Pharm., 2010, 393, 244-252.
168. Spataro G., Malecaze F., Turrin C. O., Soler V., Duhayon C., Elena P. P., Majoral J. P., Caminade A. M. Designing dendrimers for ocular drug delivery. Eur J. of Med. Chem, 2010, 45, 326-334.
169. Thankappan, U.P.; Madhusudana, N.; Desai, A.; Jayamurugan, G.; Rajesh, Y.B.R.D.; Jayaraman, N. Dendritic Poly(ether imine) based gene delivery vector. Bioconjugate Chemistry, 2011, 22, 115-119.
170. Jain, S.; Kaur, A.; Puri, R.; Utreja, P.; Jain, A.; Bhide, M.; Ratnam, R.; Singh, V.; Patil, A.S.; Jayaraman, N.; Kaushik, G.; Yadav, S.; Khanduja, K.L. Poly propyl ether imine (PETIM) dendrimer: A novel non-toxic dendrimer for sustained drug delivery. Eur. J. Med. Chem. 2010, 45, 4997-5005.
171. Neerman, N.F.; Zhang, W.; Parrish, A.R.; Simanek, E.E. In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery. Int. J. Pharm., 2004, 281, 129-132.
172. Chen, A.T.; Neerman, M.F.; Parrish, A.R.; Simanek, E.E. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for dug delivery. J. Am. Chem. Soc., 2004, 126, 10044-10048.
173. Thomas, T.P. ; Choi, S. ; Li, ML. ; KotlyarA.; Baker, J. R. Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancertargeted delivery. Bioorg. Med. Chem. Lett. 2010, 20, 5191-5194.
174. van Haandel, L.; Stobaugh, J.F. Bioanalytical method development for a generation 5 polyamidoamine folic acid methotrexate conjugated nanoparticle. Anal., Bioanal. Chem., 2010, 397, 1841-1852.
175. Shukla, R.; Thomas, T.P.; Desai, A.M.; Kotlyar, A.; Park, S.J.; Baker, J.R. HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology, 2008, 19, 295102.
176. Xu, H.; Regino, C.A.; Koyama, Y.; Hama, Y.; Gunn, A.J.; Bernardo, M.; Kobayashi, H.; Choyke, P.L.; Brechbiel, M.W. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging. Bioconjugate Chem., 2007, 18, 1474-1482.
177. Johansson, E.M.V.; Dubois, J.; Darbre, T.; Reymond, J.L. Glycopeptide dendrimer colchicine conjugates targeting cancer cells. Bioorganic & Medicinal Chemistry, 2010, 18, 6589-6597.
178. Bi, X.; Shi, X.; Majoros, I.J.; Shukla, R.; Baker, J.R. Multifunctional poly(amidoamine) dendrimer-taxol conjugates: synthesis, characterization and stability. J. Comput. Theor. Nanosci., 2007, 4, 1179-1187
179. Malik, N.; Evagorou, E.G.; Duncan, R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anti-Cancer Drugs, 1999, 10, 767-776.
180. Malik, N.; Duncan, R. US Pat.,6,585,956, 2003.
181. Malik, N.; Duncan, R. US Pat.,6,790,437, 2004.
182. Jansen, B.A.J.; van der Zwan, J.; PReedijk, J.; den Dulk, H.; Brouwer, J. A Tetranuclear platinum compound designed to overcome cisplatin resistance. Eur. J. Inorg. Chem., 1999, 1429-1433.
183. Haririan, I.; Alavidjeh, M.S.; Khorramizadeh, M.R.; Ardestani, M.S.; Ghane, Z.Z.;Namazi, H. Anionic linear-globular dendrimer-cis-platinum(II) conjugates prommote cytotoxicity in vitro against different cancer cell lines. Int. J. Nanomed, 2010, 20, 63-75.
184. Kapp, T.; Dullin, A.; Gust, R. Platinum(II)-dendrimer conjugates: synthesis and investigations on cytotoxicity, cellular distribution, platinum release, DNA, and protein binding. Bioconjugate Chem., 2010, 21, 328-337.
185. Kim, J.; Yoon, H-J.; Kim, S.; Wang, K.; Ishii, T.; Kim, Y-R.; Jang, W-D. Polymer-metal complex micelles for the combination of sustained drug releasing and photodynamic therapy. Mater. Chem., 2009, 19, 4627-4631.
186. Zhao, X.; Lee P. P.-F.; Yan, Y.-K.; Chu, C.-K. Synthesis and cytotoxic activities of chloropyridylimineplatinum(II) and chloropyridyliminecopper( II) surface-functionalized poly(amidoamine)dendrimers. J. Inorg. Biochem., 2010, 104, 105-110.
187. Zhao, X.; Yan, Y-K.; Chu, C-K.; J. Organomet. Chem. Synthesis and characterization of polyamidoamine dendrimers surface-functionalized with bromotricarbonylpyridyliminerhenium( I) units. J. Organomet. Chem., 2006, 691, 5540-5546.
188. Fu,Y.; Habtemariam, A.; Pizarro, A. M.; van Rijt, S.H.; Healey, D.J.; Cooper, P.A.; Shnyder, S.D.; Clarkson, G.J.; Sader, P.J. Organometallic osmium arene complexes with potent cancer cell cytotoxicity. J. Med. Chem., 2010, 53, 8192-8196.
189. Govender, P.; Renfrew, A.K.; Clavel, C.M.; Dyson, P.J.; Therien, B.; Smith, G.S. Antiproliferative activity of chelating N,O-and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. Dalton Transaction, 2011, 40, 1158-1167.
190. Govender, P.; Antonels, N.C.; Mattsson, J.; Renfrew, A.K.; Dyson, P.J.; Moss, J.R.; Therrien, B.; Smith, G.S. Anticancer activity of multinuclear arene ruthenium complexes coordinated to dendritic polypyridyl scaffolds. J. Organomet. Chem., 2009, 694, 3470-3476.
191. Roy, R.; Kim, J.M. Cu (II)-Self-assembling bipyridyl-glycoclusters and dendrimers bearing the Tn-antigen cancer marker: syntheses and lectin binding properties. Tetrahedron, 2003, 59, 3881-3893.
192. Tanaka, S.I.; Miyazaki, J.; Tiwari, D.K.; Jin, T.; Inouye, Y. Fluorescent platinum nanoclusters: synthesis, purification, characterization, and application to bioimaging. Angew. Chem. Int. Ed., 2011, 50, 431-435.
193. Hayder, M.; Poupot, M.; Baron, M.; Nigon, D.; Turrin, C. O.; Caminade, A. M.; Majoral, J. P.; Eisenberg, R. A.; Fournie, J. J.; Cantagrel, A.; Poupot, R.; Davignon, J. L. A Phosphorus-Based Dendrimer Targets Inflammation and Osteoclastogenesis in Experimental Arthritis. Sci. Transl. Med., 2011, 3, 81ra35.